Amgen Company Profile (NASDAQ:AMGN)

About Amgen

Amgen logoAmgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company's business segment is human therapeutics. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as Vectibix (panitumumab), Nplate (romiplostim) and Corlanor (ivabradine). The Company focuses its research and development on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience. Its products in Phase III programs include Aranesp for Myelodysplastic syndromes; ENBREL for Psoriatic arthritis and Rheumatoid arthritis remission; IMLYGIC for Metastatic melanoma, and Kyprolis for Multiple myeloma.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: AMGN
  • CUSIP: 03116210
Key Metrics:
  • Previous Close: $158.51
  • 50 Day Moving Average: $168.22
  • 200 Day Moving Average: $162.62
  • 52-Week Range: $139.02 - $176.85
  • Trailing P/E Ratio: 16.22
  • Foreward P/E Ratio: 12.74
  • P/E Growth: 1.86
  • Market Cap: $118.64B
  • Outstanding Shares: 748,360,000
  • Beta: 0.94
  • Net Margins: 33.07%
  • Return on Equity: 29.30%
  • Return on Assets: 11.45%
  • Debt-to-Equity Ratio: 0.93%
  • Current Ratio: 3.97%
  • Quick Ratio: 3.72%
Additional Links:
Companies Related to Amgen:

Analyst Ratings

Consensus Ratings for Amgen (NASDAQ:AMGN) (?)
Ratings Breakdown: 1 Sell Rating, 8 Hold Ratings, 11 Buy Ratings
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $184.50 (16.21% upside)

Analysts' Ratings History for Amgen (NASDAQ:AMGN)
DateFirmActionRatingPrice TargetDetails
9/28/2016Jefferies GroupReiterated RatingBuyView Rating Details
9/28/2016Citigroup Inc.Lower Price TargetNeutral$175.00 -> $172.00View Rating Details
9/28/2016JPMorgan Chase & Co.Reiterated RatingHoldView Rating Details
9/27/2016Goldman Sachs Group Inc.Reiterated RatingBuy$204.00 -> $206.00View Rating Details
9/22/2016BMO Capital MarketsReiterated RatingOutperform$190.00View Rating Details
9/19/2016Cowen and CompanyReiterated RatingBuyView Rating Details
9/17/2016Leerink SwannReiterated RatingHoldView Rating Details
9/17/2016Credit Suisse Group AGSet Price TargetBuy$206.00View Rating Details
9/15/2016Piper Jaffray Cos.Set Price TargetBuy$193.00View Rating Details
8/26/2016Morgan StanleyReiterated RatingOverweight$199.00 -> $198.00View Rating Details
8/26/2016GabelliInitiated CoverageHoldView Rating Details
8/26/2016Robert W. BairdReiterated RatingOutperform$157.00View Rating Details
8/5/2016ArgusReiterated RatingBuy$185.00 -> $195.00View Rating Details
7/28/2016Barclays PLCReiterated RatingEqual Weight$185.00View Rating Details
7/13/2016Bank of America Corp.Reiterated RatingHold$182.00View Rating Details
6/29/2016Sanford C. BernsteinInitiated CoverageMarket Perform$161.00View Rating Details
5/18/2016Royal Bank Of CanadaReiterated RatingBuyView Rating Details
2/23/2016BTIG ResearchReiterated RatingSell$135.00View Rating Details
1/22/2016Wells Fargo & Co.Reiterated RatingHoldView Rating Details
12/18/2015Atlantic SecuritiesInitiated CoverageOverweight$202.00View Rating Details
9/22/2015NomuraReiterated RatingBuy$190.00 -> $191.00View Rating Details
8/31/2015Raymond James Financial Inc.Initiated CoverageMarket PerformView Rating Details
8/17/2015Deutsche Bank AGReiterated RatingBuy$195.00View Rating Details
(Data available from 10/24/2014 forward)


Earnings History for Amgen (NASDAQ:AMGN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/27/2016Q316$2.79$5.73 billionListenView Earnings Details
7/27/2016Q216$2.74$2.84$5.58 billion$5.69 billionViewListenView Earnings Details
4/28/2016Q116$2.60$2.90$5.32 billion$5.53 billionViewListenView Earnings Details
1/28/2016Q415$2.29$2.61$5.53 billion$5.54 billionViewListenView Earnings Details
10/28/2015Q315$2.38$2.72$5.32 billion$5.72 billionViewListenView Earnings Details
7/30/2015Q215$2.43$2.57$5.32 billion$5.37 billionViewListenView Earnings Details
4/21/2015Q115$2.10$2.48$4.91 billion$5.03 billionViewListenView Earnings Details
1/27/2015Q414$2.05$2.16$5.20 billion$5.33 billionViewListenView Earnings Details
10/27/2014Q314$2.11$2.30$4.95 billion$5.03 billionViewListenView Earnings Details
7/29/2014Q214$2.07$2.37$4.90 billion$5.18 billionViewListenView Earnings Details
4/22/2014Q114$1.94$1.87$4.76 billion$4.52 billionViewListenView Earnings Details
1/28/2014Q413$1.69$1.82$4.81 billion$5.01 billionViewListenView Earnings Details
10/22/2013Q313$1.78$1.94$4.60 billion$4.75 billionViewListenView Earnings Details
7/30/2013Q2 2013$1.74$1.89$4.49 billion$4.68 billionViewListenView Earnings Details
4/23/2013Q1 2013$1.84$1.96$4.37 billion$4.24 billionViewN/AView Earnings Details
1/23/2013Q4 2012$1.42$1.40$4.37 billion$4.42 billionViewListenView Earnings Details
10/23/2012$1.47$1.67ViewN/AView Earnings Details
7/26/2012$1.54$1.83ViewN/AView Earnings Details
1/26/2012$1.22$1.21ViewN/AView Earnings Details
10/24/2011$1.29$1.40ViewN/AView Earnings Details
7/29/2011$1.29$1.37ViewN/AView Earnings Details
4/20/2011$1.29$1.34ViewN/AView Earnings Details
1/24/2011$1.11$1.17ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Amgen (NASDAQ:AMGN)
Current Year EPS Consensus Estimate: $11.35 EPS
Next Year EPS Consensus Estimate: $12.46 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20165$2.48$2.84$2.61
Q2 20163$2.66$2.94$2.77
Q3 20163$2.72$3.01$2.83
Q4 20163$2.64$3.03$2.82
Q1 20171$2.81$2.81$2.81
Q2 20171$2.84$2.84$2.84
Q3 20171$2.89$2.89$2.89
Q4 20171$2.97$2.97$2.97
(Data provided by Zacks Investment Research)


Current Dividend Information for Amgen (NASDAQ:AMGN)
Annual Dividend:$4.00
Dividend Yield:2.52%
Payout Ratio:40.90% (Based on Trailing 12 Months of Earnings)
35.24% (Based on Current Year Consensus EPS Estimate)
32.10% (Based on Next Year Consensus EPS Estimate)

Dividend History for Amgen (NASDAQ:AMGN)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for Amgen (NASDAQ:AMGN)
Insider Ownership Percentage: 0.20%
Institutional Ownership Percentage: 79.12%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/2/2016Annette Louise SuchVPSell3,000$174.59$523,770.00View SEC Filing  
5/4/2016Madhavan BalachandranEVPSell30,000$154.12$4,623,600.00View SEC Filing  
4/29/2016David BaltimoreDirectorSell3,312$157.21$520,679.52View SEC Filing  
4/29/2016Sean E HarperEVPSell21,875$157.99$3,456,031.25View SEC Filing  
8/31/2015Carbonnel Francois DeDirectorSell5,000$153.84$769,200.00View SEC Filing  
8/19/2015Fred HassanDirectorBuy3,010$166.63$501,556.30View SEC Filing  
6/2/2015Cynthia M PattonSVPSell4,530$157.06$711,481.80View SEC Filing  
4/23/2015Stuart A TrossSVPSell3,012$169.31$509,961.72View SEC Filing  
4/22/2015Sean E HarperEVPSell28,000$171.58$4,804,240.00View SEC Filing  
3/3/2015Stuart A TrossSVPSell4,415$157.74$696,422.10View SEC Filing  
3/2/2015David BaltimoreDirectorSell3,647$158.76$578,997.72View SEC Filing  
2/11/2015Robert A BradwayCEOSell22,000$152.69$3,359,180.00View SEC Filing  
2/5/2015Frank C HerringerDirectorBuy3,000$152.29$456,870.00View SEC Filing  
12/3/2014Carbonnel Francois DeDirectorSell3,000$168.01$504,030.00View SEC Filing  
8/5/2014Cynthia M PattonSVPSell2,644$127.97$338,352.68View SEC Filing  
8/5/2014Sean E HarperEVPSell14,000$127.29$1,782,060.00View SEC Filing  
5/21/2014Thomas J.W. DittrichCAOSell4,130$112.83$465,987.90View SEC Filing  
4/28/2014A Kelly MichaelCFOSell2,065$110.45$228,079.25View SEC Filing  
3/6/2014Carbonnel Francois DeDirectorSell1,000$126.69$126,690.00View SEC Filing  
9/4/2013Madhavan BalachandranEVPSell18,000$112.76$2,029,680.00View SEC Filing  
8/28/2013David BaltimoreDirectorSell4,582$109.66$502,462.12View SEC Filing  
5/22/2013Thomas J.W. DittrichCAOSell6,130$104.78$642,301.40View SEC Filing  
5/21/2013Madhavan BalachandranEVPSell6,000$103.28$619,680.00View SEC Filing  
5/17/2013Rebecca M HendersonDirectorSell8,421$105.72$890,268.12View SEC Filing  
5/16/2013Cynthia M PattonSVPSell3,544$105.01$372,155.44View SEC Filing  
5/14/2013Judith C PelhamDirectorSell25,000$108.25$2,706,250.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Amgen (NASDAQ:AMGN)
News IconActive biotech company shares in the news: Amgen Inc. (NASDAQ:AMGN), Galena Biopharma, Inc. (NASDAQ:GALE) - The Voice Registrar (NASDAQ:AMGN) - October 24 at 3:31 PM
News IconUpcoming Earnings Report: Amgen Inc. (NASDAQ:AMGN) - The Voice Registrar (NASDAQ:AMGN) - October 24 at 3:31 PM
News IconIs Amgen Inc.(NASDAQ: AMGN), a large market cap stock a smart buy? - The Daily Leicester (NASDAQ:AMGN) - October 23 at 3:27 PM logoTop Health Care Earnings Coming Next Week (NASDAQ:AMGN) - October 23 at 3:27 PM
News IconAmgen Inc. (AMGN) Position Decreased by CAM Group Holding A S ... - DailyQuint (NASDAQ:AMGN) - October 22 at 3:27 PM
News IconAmgen Inc. (NASDAQ:AMGN) Analysts Recommendations and Insider Trading - The Independent Republic (NASDAQ:AMGN) - October 21 at 8:32 PM
News IconAmgen Inc. (NASDAQ:AMGN) from Biotechnology – Todays Top Gains (NASDAQ:AMGN) - October 21 at 3:29 PM logoWill Amgen (AMGN) Sustain its Earnings Beat Trend in Q3? - Nasdaq (NASDAQ:AMGN) - October 21 at 12:42 PM
News IconBank of Hawaii reached $2,799,000 position of Amgen Inc. (AMGN ... - DailyQuint (NASDAQ:AMGN) - October 21 at 12:42 PM logoThe Zacks Analyst Blog Highlights: Pfizer, Novartis AG, Amgen, Merck and Momenta Pharmaceuticals (NASDAQ:AMGN) - October 21 at 12:42 PM logoAmgen's (AMGN) Xgeva Meets Endpoint in Phase III Study (NASDAQ:AMGN) - October 21 at 12:42 PM logoWill Amgen (AMGN) Sustain its Earnings Beat Trend in Q3? (NASDAQ:AMGN) - October 21 at 12:42 PM logoIndex funds can be inferior to active funds in two crucial ways (NASDAQ:AMGN) - October 21 at 12:42 PM logo4:20 pm Amgen announces that a Phase 3 study evaluating XGEVA vs zoledronic acid met the primary endpoint in patients with multiple myeloma (NASDAQ:AMGN) - October 20 at 9:21 PM logoAmgen Announces Positive Top-Line Results From XGEVA® (Denosumab) Phase 3 Trial For Delay Of Bone Complications In Multiple Myeloma Patients (NASDAQ:AMGN) - October 20 at 9:21 PM
News IconIntraday Active Biotech Stocks News: Kite Pharma, Inc. (NASDAQ ... - The Voice Registrar (NASDAQ:AMGN) - October 20 at 3:54 PM
News IconHot Watch to Target- Amgen Inc.'s (AMGN) | Hot Stocks Point - Hot Stocks Point (NASDAQ:AMGN) - October 20 at 3:54 PM
News Icon13F Activity: Amgen INC (AMGN) Holder Eastern Bank Has Raised ... - Chester News (NASDAQ:AMGN) - October 20 at 3:54 PM logoAmgen Partner Kite Not 'A One-Trick Pony'; Pipeline Grows In 2017 (NASDAQ:AMGN) - October 20 at 3:54 PM logoWhat Biogen Is Doing that Put It in Good Favor with Analysts (NASDAQ:AMGN) - October 20 at 9:19 AM
News IconAfter Today's Bearish Options Activity, Is Amgen, Inc.'s Near-Term Analysis Positive? - Frisco Fastball (NASDAQ:AMGN) - October 19 at 4:18 PM
News IconBiotech Companies To Look Out For: Amgen Inc. (AMGN), Kite Pharma, Inc. (KITE) - The Independent Republic (NASDAQ:AMGN) - October 19 at 4:18 PM
News IconInstitutional Heat: Amgen Incorporated Common Stock Usd0.0001 (AMGN) Shareholder Schroder Investment ... - Chester News (NASDAQ:AMGN) - October 19 at 4:18 PM
News IconNoteworthy Analyst Ratings of Two Stocks: Marathon Petroleum Corporation (NYSE:MPC), Amgen Inc. (NASDAQ:AMGN) - The Voice Registrar (NASDAQ:AMGN) - October 19 at 8:19 AM logoWhy Vertex Lowered Its Guidance for Orkambi (NASDAQ:AMGN) - October 19 at 8:19 AM
News IconUpdate on Amgen Inc. (NASDAQ:AMGN) for the day (NASDAQ:AMGN) - October 18 at 3:29 PM logo3 Notable Runners: Amgen Inc. (AMGN), Swift Transportation Company (SWFT), Enterprise Products Partners L.P. (EPD) - iStreetWire (NASDAQ:AMGN) - October 17 at 3:26 PM
News IconVolatile Stock to Watch - Amgen Inc.'s (AMGN) - Hot Stocks Point (NASDAQ:AMGN) - October 17 at 3:26 PM
News IconAdvanced Micro Devices, Inc. (NASDAQ:AMD) & Amgen, Inc. (NASDAQ:AMGN) Traders Recap - Money News (NASDAQ:AMGN) - October 17 at 3:26 PM logoAmgen to Pay $1 Per Share 4Q Dividend (AMGN) (NASDAQ:AMGN) - October 17 at 3:26 PM
News IconLeading stocks in today’s market: Amgen Inc. (NASDAQ:AMGN) (NASDAQ:AMGN) - October 16 at 3:26 PM
News IconA look at a High Market Cap Stock: Amgen Inc., AMGN – The Daily ... - The Daily Leicester (NASDAQ:AMGN) - October 16 at 8:17 AM
News IconActive Mover – Amgen Inc.'s (AMGN) - Hot Stocks Point (NASDAQ:AMGN) - October 14 at 3:28 PM
News IconAmgen Inc. (NASDAQ: AMGN) – Is this large market cap stock undervalued? - The Daily Leicester (NASDAQ:AMGN) - October 13 at 8:50 PM
News IconAmgen Inc. (NASDAQ:AMGN) Quarterly Analysis - The Newburgh Press (NASDAQ:AMGN) - October 13 at 12:53 PM
News IconSell-side Taking Aim at Shares of Amgen Inc. (NASDAQ:AMGN ... - CSZ News (NASDAQ:AMGN) - October 12 at 8:48 PM
News IconTop Earnings to Watch for: Amgen Inc. (NASDAQ:AMGN) - The Voice Registrar (NASDAQ:AMGN) - October 12 at 8:48 PM logoAmgen, Inc. : AMGN-US: Dividend Analysis : August 17th, 2016 (record date) : By the numbers : October 12, 2016 (NASDAQ:AMGN) - October 12 at 3:41 PM logoTrading the biotech sell-off (NASDAQ:AMGN) - October 12 at 3:41 PM logoHow to Play a Down and Out Amgen, Inc. (AMGN) Stock (NASDAQ:AMGN) - October 12 at 10:57 AM
News IconTime To Put On The Watch List? - Amgen Inc. (NASDAQ:AMGN), Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) - The Voice Registrar (NASDAQ:AMGN) - October 11 at 8:31 PM
News IconAmgen Inc. (NASDAQ:AMGN) missed earnings on 0 occasions | The ... - The Independent Republic (NASDAQ:AMGN) - October 11 at 8:31 PM
News IconBiotech Stocks Worth Chasing: Amgen Inc. (AMGN), Opko Health, Inc. (OPK) - The Independent Republic (NASDAQ:AMGN) - October 11 at 8:31 PM logoBiotech bloodbath (NASDAQ:AMGN) - October 11 at 8:31 PM logoFinal Trade: AMGN, OLED, & more (NASDAQ:AMGN) - October 11 at 8:31 PM logoAmgen Reports Positive Cancer Drug Results (AMGN) (NASDAQ:AMGN) - October 11 at 3:29 PM
News IconAnalysts Valuations For Two Stocks: Amgen, Inc. (NASDAQ:AMGN), McKesson Corporation (NYSE:MCK) - The Voice Registrar (NASDAQ:AMGN) - October 10 at 3:24 PM
News IconBiotech Stocks Worth Chasing: Amgen Inc. (AMGN), Celldex ... - The Independent Republic (NASDAQ:AMGN) - October 10 at 3:24 PM
News IconTrading the Biotech News: Biogen Inc. (NASDAQ:BIIB), Amgen Inc. (NASDAQ:AMGN) - The Voice Registrar (NASDAQ:AMGN) - October 10 at 3:24 PM logoBRIEF-Amgen says new retrospective analyses confirm Vectibix treatment provided survival benefit over chemotherapy with or without Bevacizumab (NASDAQ:AMGN) - October 10 at 9:51 AM


Amgen (NASDAQ:AMGN) Chart for Monday, October, 24, 2016

Last Updated on 10/24/2016 by Staff